Biosimilars Market Size, Share & Trends Report

Biosimilars Market Size, Share & Trends Analysis By Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins), By Application (Rheumatoid Arthritis, Oncology), By Region And Segment Forecasts 2023 - 2030

Report ID: 978-1-68038-916-6
Number of Pages: 70
Format: Electronic (PDF)

Historical Range: 2018 - 2021
Industry: Healthcare

Market Segmentation

Biosimilars Product Outlook (Revenue, USD Billion, 2018 - 2030)
- Recombinant Non-glycosylated Proteins
- RecombinantGlycosylated Proteins
Biosimilars Application Outlook (Revenue, USD Billion, 2018 - 2030)
- Oncology
- Blood Disorders
- Growth Hormonal Deficiency
- Rheumatoid Arthritis
- Chronic & Autoimmune Disorders
- Others
Biosimilars Regional Outlook (Revenue, USD Billion, 2018 - 2030)
- North America
  - North America Biosimilars Market, By Product
    - Recombinant Non-glycosylated Proteins
    - RecombinantGlycosylated Proteins
  - North America Biosimilars Market, By Application
    - Oncology
    - Blood Disorders
    - Growth Hormonal Deficiency
    - Rheumatoid Arthritis
    - Chronic & Autoimmune Disorders
    - Others
  - U.S.
    - U.S. Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - U.S. Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - Canada
    - Canada Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Canada Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
- Europe
  - Europe Biosimilars Market, By Product
    - Recombinant Non-glycosylated Proteins
    - RecombinantGlycosylated Proteins
  - Europe Biosimilars Market, By Application
    - Oncology
    - Blood Disorders
    - Growth Hormonal Deficiency
    - Rheumatoid Arthritis
    - Chronic & Autoimmune Disorders
    - Others
  - UK
    - UK Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - UK Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - Germany
    - Germany Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Germany Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - France
    - France Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - France Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - Italy
    - Italy Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Italy Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - Spain
    - Spain Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Spain Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - Sweden
    - Sweden Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Sweden Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - Norway
    - Norway Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Norway Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - Denmark
    - Denmark Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Denmark Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
- Asia Pacific
  - Asia Pacific Biosimilars Market, By Product
    - Recombinant Non-glycosylated Proteins
    - RecombinantGlycosylated Proteins
  - Asia Pacific Biosimilars Market, By Application
    - Oncology
    - Blood Disorders
    - Growth Hormonal Deficiency
    - Rheumatoid Arthritis
    - Chronic & Autoimmune Disorders
    - Others
  - China
    - China Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - China Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - Japan
    - Japan Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Japan Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - India
    - India Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - India Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - Australia
    - Australia Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Australia Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - Thailand
    - Thailand Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Thailand Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - South Korea
    - South Korea Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - South Korea Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
- Latin America
  - Latin America Biosimilars Market, By Product
    - Recombinant Non-glycosylated Proteins
    - RecombinantGlycosylated Proteins
  - Latin America Biosimilars Market, By Application
    - Oncology
    - Blood Disorders
    - Growth Hormonal Deficiency
    - Rheumatoid Arthritis
    - Chronic & Autoimmune Disorders
    - Others
  - Brazil
    - Brazil Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Brazil Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - Mexico
    - Mexico Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Mexico Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - Argentina
    - Argentina Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Argentina Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
- Middle East and Africa
  - Middle East and Africa Biosimilars Market, By Product
    - Recombinant Non-glycosylated Proteins
    - RecombinantGlycosylated Proteins
  - Middle East and Africa Biosimilars Market, By Application
    - Oncology
    - Blood Disorders
    - Growth Hormonal Deficiency
    - Rheumatoid Arthritis
    - Chronic & Autoimmune Disorders
    - Others
  - Saudi Arabia
    - Saudi Arabia Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Saudi Arabia Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - South Africa
    - South Africa Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - South Africa Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - UAE
    - UAE Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - UAE Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others
  - Kuwait
    - Kuwait Biosimilars Market, By Product
      - Recombinant Non-glycosylated Proteins
      - RecombinantGlycosylated Proteins
    - Kuwait Biosimilars Market, By Application
      - Oncology
      - Blood Disorders
      - Growth Hormonal Deficiency
      - Rheumatoid Arthritis
      - Chronic & Autoimmune Disorders
      - Others

Biosimilars Market Dynamics

Driver: Increasing prevalence of chronic diseases

Cancer is considered as one of the major cause of illness and has both social and economic impact on individuals. According to report published by WHO in 2018 over 9.6 million deaths were caused due to cancer globally. The same source estimated that about 1 in 6 deaths are caused due to cancer. Over 70% of deaths occur in middle- and low-income countries. Cancer is estimated to cost more than USD 4.5 billion in direct health system costs. During 2016-18 Australia received a funding of USD 252 million to enhance cancer research projects as well as cancer related programs. Also, in December 2019, the government of U.S. raised a funding of USD 2.6 billion in order to increase medical research and also an increase of USD 296 million for cancer research funding was provided by the government. In addition, rise in the Medicare caps for the U.S. territories and Puerto Rico for two years is quite critical in helping various cancer patient treatment and also the follow up care.

Driver: Cost-effectiveness of biosimilar drugs

Rapid growth of biotechnology industry has created the demand for safe and cost-effective medicines in an effort to curtail the existing healthcare expenditure. Biosimilars have proven to be less expensive than comparator’s (originator’s) drugs as due to cost-effective manufacturing processes. Various studies indicate towards the fact that biosimilars, which are derivatives of living organisms fit the cost-effectiveness ratio. Biosimilars have been proven to be of slightly lower or almost equal effectivity in comparison to their respective reference biopharmaceuticals. Two key factors that are anticipated to healthcare industry due to the advent of biosimilars are decreased unit cost of biologics and increased volume of biosimilar drugs.

Restraint: High manufacturing complexities and costs

Biologics are complex and large molecules that have specific effects. In many cases they are antibodies or proteins such as G-CSF. One of the main concerns to be observed is that some modifications might occur during the process of manufacturing that is most of the times undetectable and lead to altered immunogenicity, efficacy, or toxicity. Due to this many physicians are worried to prescribe biosimilars rather than biologics to their patients as the physician would not know whether the biosimilar is suitable for the patient until and unless the drug loses its efficacy suddenly or until the patient develops toxicity due to biosimilars. The cost of development of biosimilars is much higher than of generics that are chemical based.

What Does This Report Include?

This section will provide insights into the contents included in this biosimilars market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Biosimilars market qualitative analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Biosimilars market quantitative analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.